Lantern Pharma’s Triple Threat: Inflation, Global Tensions, and Pandemic Impacts Jeopardize Financial Health

Lantern Pharma, Inc. (LTRN) has disclosed a new risk, in the Economy & Political Environment category.

Lantern Pharma, Inc. faces heightened business risks due to the interplay of unfavorable geopolitical and macroeconomic developments globally. Mounting inflation rates and the ongoing COVID-19 pandemic repercussions, coupled with geopolitical tensions stemming from the Ukrainian/Russian and Israeli/Palestinian conflicts, have introduced considerable uncertainties. These conditions threaten to escalate operating costs, disrupt supply chains, and impair access to capital for the company. The volatility in global financial markets further exacerbates the risk, potentially undermining Lantern Pharma’s financial stability and operational results.

Overall, Wall Street has a Hold consensus rating on LTRN stock based on 1 Hold.

To learn more about Lantern Pharma, Inc.’s risk factors, click here.